STOCKS TELEGRAPH

Tag: Sesen Bio

  • Sesen Bio Inc. (SESN) Shareholders Bear Fruits of Merger

    Sesen Bio Inc. (NASDAQ: SESN) has made the news lately, as its merging partner, Carisma Therapeutics has gone on to up its dividend payment from $25 million to a whopping $70 million. This bodes well for the future of the combined entities and hints toward a path of shared value creation.

    Sesen Bio Shareholders Receive Generous Dividends

    Sesen Bio Inc. (SESN) finds itself in the spotlight of the wider market, given a recent news update, relating to its merger agreement with the private pharmaceutical company, Carisma Therapeutics Inc. As part of the agreement, Sesen shareholders will be receiving a cash dividend of $0.34 per share, amounting to over $70 million, in total. This update comes after the previously stated amount was initially set at $25 million in total or $0.12 per individual share. This ‘treat’ to investors comes in addition to an earlier commitment made worth $30 million, which the management of Carisma claims to still stand by. This merger agreement is clearly in line with the best interests of the shareholders, as well as its future.

    SESN Merger Overview

    Looking into the planned merger between Sesen Bio and Carisma, it is clear that there are clear long-term benefits that shareholders face exposure to, in addition to the immediate cash dividend. The joint entity would boast the combined technical know-how, capability, and intellectual properties of both companies while enabling effective research to see carried out. The decision to merge comes after a rigorous assessment by the SESN board, which also considered liquidation as a strong option. After looking at 42 bid proposals, the board deemed Carisma as being the most optimal player to merge with.

    Conclusion

    SESN stock is on the verge of drastic change in its merger with Carisma Therapeutics. The $70 million cash payment paid to its shareholders is part of a long-term collaboration of joint success.

  • Best Penny Stocks for 2021

    Are penny stocks the right start for you to invest in stocks? What are the best penny stocks under $5 in 2021? Not sure if you should make a decent investment in penny stocks or rather spend all your savings on the cherry-picked blue-chip stocks?

    Here’s the CODE to remember while investing in stocks.

    People often look at billion-dollar companies with premium share prices of $500 to consider them valuable. However, this is a common misconception because the stock’s share price does not always have something to do with the value of the stock. In reality, price holds very little sway compared to the value of the stock. Instead, it’s the value of the stock and potential in stock’s fundamentals and metrics that define if the present value of the stock makes it worth it or not.

    In other words, stocks under $5 in price can make you the same percentage of profit as a $500 stock can. All you have to do is know the right trends, developments, and measures for investing in the best stocks.

    In this article, we are going to give you the 5 penny stocks of the year that have the best potential to make you rich. We will also provide you with the key measures to learn how to invest in valuable penny stocks.

    Ocean Power Technologies (OPTT)

    First on our list of $5 stocks is Ocean Power Technologies (OPTT), which was the latest target of the raging meme stock phenomenon. It is a leading company in renewable wave energy technology. Its proprietary technology allows it to convert ocean waves into electrical energy. As the world drives towards global green and renewable energy, OPTT stock is going to see big future gains. OPTT stock is valued at 130 million and reported a strong liquidity position of $80.4 million cash in total for the fiscal quarter ended on 30th January 2021. OPTT increased efficiency by reducing its operating expense by 4.3% to $2.78 million in the quarter ended on 30th January. It has recently acquired a technology company for offshore engineering services known as trident technology. OPTT aims to expand its customer base and technology installation-deployment contracts, making this a very potent stock to invest in.

    Atlantic American Corporation (AAME)

    Next on our list of $5 stocks is Atlantic American Corporation (AAME). It is one of the best performing life insurance companies in 2021 that offers insurance products like life, health, property, and casualty insurance policies. The company has a market cap of 86.971 million. Atlantic was affected by the disruption caused by the pandemic, which led to a material decline in capital markets. But despite that, AAME managed to increase its premium revenue to $46.1 million in the first quarter of 2021. Operating loss was reduced to $2.0 million. According to the company’s income statement, the stock had an ROI of 112% for its investors since the start of the year. The company reported $200 million in 2020 and is expected to increase its revenue growth in 2021 since the effect of the pandemic is fading. AAME stock, which has a $0.02 quarterly dividend, is appropriate for income investors since it issues a dividend quarterly.

    Sesen Bio (SESN)

    The third stock in the list of under $5 stocks is Sesen Bio (SESN). It is a late-stage clinical company that uses the proprietary treatment of cancer using Targeted Fusion Protein Therapeutic. SESN has been churning revenue and increasing share price for the past 12 months. The share price started at 1.30 dollars this year and is currently around the 4 dollar mark. The price of the SESN stock has risen by 472% from the past year. The market cap is at 722.607 million dollars. Its lead candidate is the real-money maker, which is known as Vicineum. Vicineum is going through trials and tests to treat bladder cancer as well as head and neck cancer. This broad cancer treatment showed a 71% non-recurrence rate in Phase 2 trials. It is also expected to gain regulatory approvals by 2021 in the US and by 2022 in Europe. Therefore, investors can jump on this bandwagon and expect it to cross the $5 mark after the approval period.

    AmpliTech Group (AMPG)

    Fourth, on our list of investing in penny stocks is AmpliTech Group (AMPG). This stock is known as the 5G revolution stock. 5G industry is still relatively a very early stage market. But that is exactly what makes this stock a potentially profitable long-term buy option. Its diversified portfolio, including the internet of things, space technology, and defense technology, will immediately get a boost in contract demands and revenue once fused with 5G technology. In addition, the company has a debt-to-equity ratio of 0.24, which shows that majority of the company’s operations have not been funded by debt but own capital. Currently, the AMPG stock is almost touching the $5 mark. According to Investopedia, this $45.877 million market cap stock will exit the penny stock category by a strong margin once the 5G starts rolling and is expected to grow 30% in the near term thanks to a recent $23 million capital raise from winning a contract from Fortune 100 defense contractor. In the first quarter of 2021, the company reported a backlog of $2.4 million.

    Mind Medicine (MNMD)

    Our final selection for the under $5 stock is a euro pharmaceutical stock that is as significant, if not more, as the rest of the 4 penny stocks. It is called Mind Medicine (MNMD). It has a competitive advantage in the pharmaceutical sector because it targets and deals with psychedelics. MNMD stock is currently under the $4 mark. The company has a solid debt-to-equity ratio of 0.07. The total equity has risen by a whopping 855% in the quarter ending on 30th January compared to the prior quarter. This 847.955 million dollars valued company will see significant boosts once it gains regulatory approvals, an observed trend in biotech stocks. The company is offering experiential therapy through LSD administration for treating mental health issues. This psychedelic stock is only possible in this timeline because of growing acceptance and approvals by local and state regulators to use drugs for medicinal or recreational purposes. Because of this, Mind Medicine believes it can target an addressable market that could grow by $16 trillion by 2030.